UroGen Pharma Ltd. (URGN) Stock Price & Analysis

UroGen Pharma Ltd. (URGN) closed at USD 33.75 on Wednesday, October 28, 2026, down 0.47% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 33.91; the Oct 28, 2026 session ranged USD 33.1–34.04 on volume of 1,587,964 shares. Market capitalization is $1.65B, with a 52-week range of USD 16.5–50.81 (NGM). Source: Nexqual, retrieved October 29, 2026 at 13:07 UTC.

Also available as compact Markdown for AI agents: nexqual.com/URGN.md

Key facts (URGN)

• Last four reported quarters (through Jun 30, 2026): revenue $189M, net income -$97.6M (-51.7% margin), free cash flow -$159M (SEC filings).
• 1 of 80 tracked superinvestors hold URGN (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
• Insider open-market sales, last ~7 months: 8 Form 4 filings, $4.2M; 5 not under a Rule 10b5-1 plan ($3.2M); 0 by opportunistic insiders, 7 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.00 on a 1–5 scale) (8 analysts), mean target USD 60 (range 48–75).
• Total return with dividends: 1Y +70.6% vs S&P 500 +13.6%; 5Y +96.2% vs S&P 500 +79.8%.
• Next earnings: 2026-11-04, EPS estimate USD 0.09, revenue estimate $89.8M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (URGN)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (URGN)

P/S 8.7x · EV/Sales 9.2x · FCF yield -9.65% · Earnings yield -5.92% · Net debt $92.0M · EV $1.74B

Superinvestors (SEC 13F-HR, Q2 2026) (URGN)

1 of 80 tracked investors hold URGN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider sales (SEC Form 4, open-market, last ~7 months) (URGN)

3 of 8 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (URGN)

Consensus Buy (mean 2.00 on a 1–5 scale), 8 analysts; mean target USD 60 (low 48, high 75).

Rating changes, last 120 days:

Total return (dividends reinvested) (URGN)

URGN earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

URGN recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

URGN suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 2, 2026.

Companies that name URGN in their SEC reports

URGN company outlook (results filed Aug 5, 2026)

• “Guidance: The Company continues to expect 2026 net product revenue for JELMYTO to be in the range of $97 million to $101 million.”
• “The Company is not providing full-year 2026 revenue guidance for ZUSDURI at this time, as the product remains in the early stages of its commercial launch.”
• “The Company is increasing its full-year 2026 operating expenses guidance to be in the range of $260 million to $270 million, including non-cash share-based compensation expense of $20 million to $24 million.”

Quoted word-for-word from the SEC 8-K results press release.

URGN analyst estimates and revisions

URGN options: expected move

Options price a move of about ±20.4% (±$6.93) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±10.5% on average.

30-day implied volatility 69.9% vs 41.6% realized over the last 30 trading days. Put/call ratio (volume) 0.08. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 13:07 UTC)

Technical Analysis (URGN)

Nexqual's technical model rates URGN "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 13:07 UTC.

Analyst Ratings (URGN)

Wall Street analysts rate URGN "Buy" based on 8 analysts, with a mean price target of USD 60 (range USD 48–75), per Nexqual as of October 29, 2026 at 13:07 UTC.

Earnings (URGN)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 13:07 UTC.

Financials & Fundamentals (URGN)

Source: Nexqual, October 29, 2026 at 13:07 UTC.

Financial Health Score (URGN)

Nexqual rates UroGen Pharma Ltd.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 13:07 UTC.

Ownership (URGN)

Source: Nexqual, October 29, 2026 at 13:07 UTC.

Leadership (URGN)

UroGen Pharma Ltd. is led by Elizabeth A. Barrett, President, CEO & Director, per Nexqual as of October 29, 2026 at 13:07 UTC.

Major Backers & Investors (URGN)

Notable institutional backers of UroGen Pharma Ltd. include RTW Investments LP, Morgan Stanley, Kynam Capital Management, LP, according to Nexqual as of October 29, 2026 at 13:07 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 13:07 UTC.

From UroGen Pharma Ltd.'s Latest SEC 10-K Filing (filed 2026-03-02)

Key Strengths & Strategy (as disclosed to the SEC)

• In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study evaluating the efficacy and safety of UGN-103 in patients with recurrent low-grade intermediate risk NMIBC.
• We have developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs.
• Jelmyto consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release RTGel technology.
• Zusduri, which consists of mitomycin and sterile hydrogel, uses our proprietary sustained release RTGel technology and is delivered directly into the bladder in an out-patient procedure by a trained healthcare professional using a urinary catheter to enable the treatment of tumors by non-surgical means.

Partnerships

• In November 2025, we provided notice to terminate the license agreement with Agenus in connection with our decision to discontinue development of UGN-301.

Legal & Regulatory Risks (Item 1A, quoted)

• Our product candidates may not receive the requisite approvals for commercialization, or we may need to conduct additional nonclinical experiments and clinical trials, provide additional data and information, and meet additional standards for regulatory approval.
• We expect current and future legislation affecting the healthcare industry, including healthcare reform, to impact our business generally and to increase limitations on reimbursement, rebates and other payments, which could adversely affect third-party coverage of our products, our operations, and/or how much or under what circumstances healthcare providers will prescribe or administer our products, if approved.
• The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably.
• We may be unable to obtain Orphan Drug Designation or exclusivity for future product candidates we may develop.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 13:07 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt